Author Interviews, Multiple Sclerosis / 19.01.2022
Multiple Sclerosis: Hydroxychloroquine May Benefit Some Patients with Most Severe Disease
MedicalResearch.com Interview with:
Marcus Koch MD PhD
Associate Professor of Neurology
Multiple Sclerosis Program
University of Calgary
MedicalResearch.com: What is the background for this study?
Response: Primary progressive multiple sclerosis (PPMS) is the least common, but also the least treatable form of multiple sclerosis. PPMS does not react well to commonly used MS treatments. We believe that this is at least in part because PPMS is driven by other disease mechanisms.
One disease mechanism that we believe is important in PPMS is microglial activation. Microglial cells are a type of cell in the brain and spinal cord that normally have beneficial functions, such as clearing debris or assisting repair after injury. In PPMS however, microglial cells are chronically active, and we believe that this chronic microglial activation contributes to tissue damage.
(more…)